Chronic inflammation disease biotechnology company Evommune applies for a US IPO aiming to raise $100 million
I'm PortAI, I can summarize articles.
Biotechnology company Evommune submitted an IPO application to the U.S. Securities and Exchange Commission on Thursday, planning to raise up to $100 million. The company focuses on the treatment of chronic inflammatory diseases, with its core candidate drug EVO756 currently undergoing Phase 2b clinical trials, with results expected to be announced in 2026. Evommune was founded in 2020 and plans to list on the New York Stock Exchange under the ticker symbol EVMN
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments